JP2016534088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534088A5 JP2016534088A5 JP2016526506A JP2016526506A JP2016534088A5 JP 2016534088 A5 JP2016534088 A5 JP 2016534088A5 JP 2016526506 A JP2016526506 A JP 2016526506A JP 2016526506 A JP2016526506 A JP 2016526506A JP 2016534088 A5 JP2016534088 A5 JP 2016534088A5
- Authority
- JP
- Japan
- Prior art keywords
- ion
- ions
- formula
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 N-acetyl-piperidinyl- Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 206010006451 bronchitis Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 229940085991 phosphate ion Drugs 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 229940006460 bromide ion Drugs 0.000 claims 1
- 230000007883 bronchodilation Effects 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 1
- 229940006461 iodide ion Drugs 0.000 claims 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176483 | 2013-07-15 | ||
| EP13176483.9 | 2013-07-15 | ||
| PCT/EP2014/063964 WO2015007519A1 (en) | 2013-07-15 | 2014-07-01 | Novel benzimidazolium compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534088A JP2016534088A (ja) | 2016-11-04 |
| JP2016534088A5 true JP2016534088A5 (enExample) | 2017-08-10 |
| JP6461134B2 JP6461134B2 (ja) | 2019-01-30 |
Family
ID=48783091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526506A Active JP6461134B2 (ja) | 2013-07-15 | 2014-07-01 | 新規ベンゾイミダゾリウム化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9328131B2 (enExample) |
| EP (1) | EP3022196B1 (enExample) |
| JP (1) | JP6461134B2 (enExample) |
| WO (1) | WO2015007519A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006332726B2 (en) | 2005-12-28 | 2012-12-13 | Vertex Pharmaceuticals Incorporated. | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| JP6461948B2 (ja) | 2013-07-15 | 2019-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規５−置換ベンゾイミダゾリウム化合物 |
| SG10201902963PA (en) | 2014-10-06 | 2019-05-30 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| EP3245202B1 (en) * | 2015-01-12 | 2020-03-11 | Boehringer Ingelheim International GmbH | Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| WO2017028926A1 (en) * | 2015-08-20 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Novel annelated benzamides |
| EA035738B1 (ru) * | 2015-08-20 | 2020-08-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Аннелированные феноксиацетамиды |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250527A (en) * | 1985-10-24 | 1993-10-05 | Smithkline & French Laboratories Limited | Pyridyl containing benzimidazoles, compositions and use |
| US6858615B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| EP1663235B1 (en) * | 2003-08-18 | 2013-07-24 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7399766B2 (en) * | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| US7807834B2 (en) * | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| JP2008110935A (ja) * | 2006-10-30 | 2008-05-15 | Kowa Co | ２−フェニルベンゾイミダゾール誘導体を有効成分とするｓｔａｔ６活性化阻害剤 |
| EA201001848A1 (ru) * | 2008-06-10 | 2011-08-30 | Новартис Аг | Производные пиразина в качестве блокаторов эпителиальных натриевых каналов |
| WO2011079087A1 (en) * | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
-
2014
- 2014-07-01 EP EP14734164.8A patent/EP3022196B1/en active Active
- 2014-07-01 WO PCT/EP2014/063964 patent/WO2015007519A1/en not_active Ceased
- 2014-07-01 JP JP2016526506A patent/JP6461134B2/ja active Active
- 2014-07-14 US US14/330,020 patent/US9328131B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534088A5 (enExample) | ||
| JP2016527220A5 (enExample) | ||
| HRP20191339T1 (hr) | Novi anelirani fenoksiacetamidi | |
| JP2018529657A5 (enExample) | ||
| HRP20171614T1 (hr) | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju | |
| JP2016532677A5 (enExample) | ||
| JP2014534222A5 (enExample) | ||
| JP2011162556A5 (enExample) | ||
| EP4424311A3 (en) | Pyrrolopyrimidines as cftr potentiators | |
| CY1116994T1 (el) | 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ (2,3,4,5,6-πενταϋδροξυεξυλ) amino) αιθοξυ) φαινυλ) βουτυλ) καρβαμιμιδοϋλ) πυραζινο-2-καρβοξαμιδιο | |
| JP2014097964A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| CL2008001982A1 (es) | Acido (2s)-2-{[3´-cloro-4´-[2,2-dimetilpirrolidin-1-il) carbonil]-5-fluorobifenil-2-il]oxi}propanoico y su sal 2-metilpropan-2-amina; formas cristalinas de la sal y del acido libre; compuestos intermediarios; y uso en el tratamiento de asma, rinitis y enfermedad pulmonar obstructiva cronica. | |
| JP2014500861A5 (enExample) | ||
| JP2012503668A5 (enExample) | ||
| MY159172A (en) | Inhalable particles comprising tiotropium | |
| TW200708513A (en) | Novel crystalline forms of tiotropium bromide | |
| JOP20200314A1 (ar) | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة | |
| JP2012532191A5 (enExample) | ||
| JP2013538857A5 (enExample) | ||
| JP2016529248A5 (enExample) | ||
| RU2013153202A (ru) | Композиции для ингалятора сухого порошка, содержащие умеклидиний | |
| WO2009019598A3 (en) | Inhalation therapy for respiratory disorders | |
| JP2016526563A5 (enExample) |